博雅生物(300294) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥448,452,537.26, a decrease of 44.36% compared to ¥805,928,136.64 in the same period last year[5] - Net profit attributable to shareholders for Q1 2024 was ¥152,024,886.81, down 10.74% from ¥170,317,490.97 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥127,306,750.41, a decrease of 7.63% from ¥137,815,331.11 year-on-year[5] - Basic and diluted earnings per share for Q1 2024 were both ¥0.30, a decline of 11.76% from ¥0.34 in the previous year[5] - The net profit for the period is reported at ¥151,760,842.43, compared to ¥174,373,215.65 in the previous period, showing a decrease of about 12.92%[27] - The total comprehensive income amounted to 151,760,842.43, down from 174,373,215.65, indicating a decrease of about 13.0%[28] - Basic and diluted earnings per share were both 0.30, compared to 0.34 in the previous period, reflecting a decline of approximately 11.8%[28] - The company reported a net profit of ¥151,760,842.43 for the current period, down 14.5% from ¥177,373,215.65 in the previous period[39] Cash Flow and Assets - The net cash flow from operating activities was ¥123,871,710.13, down 44.37% from ¥222,678,836.22 in the same quarter last year[5] - Cash flow from operating activities was 410,436,128.44, significantly lower than 782,399,226.54, representing a decrease of about 47.5%[28] - The company's cash and cash equivalents at the end of Q1 2024 amount to ¥1,860,435,345.29, down from ¥1,961,478,737.03 at the beginning of the period, representing a decrease of approximately 5.14%[12] - The net increase in cash and cash equivalents was -105,345,193.69, contrasting with a positive increase of 179,436,811.37 in the previous period[31] - Total assets at the end of Q1 2024 were ¥7,992,850,470.88, an increase of 2.09% from ¥7,828,900,301.89 at the end of the previous year[5] - The total current assets rose to 6,612,770,411.54 from 6,427,633,042.37, indicating an increase of about 2.9%[36] - The total non-current assets decreased to 1,380,080,059.34 from 1,401,267,259.52, reflecting a decline of approximately 1.5%[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,406[10] - The largest shareholder, China Resources Pharmaceutical Group, holds 29.28% of shares, totaling 147,640,553 shares[10] - The number of shares held by the top ten shareholders includes significant stakes from institutional investors, with the second-largest shareholder holding 11.31%[10] Operating Costs and Expenses - The company reported a significant decrease in operating costs, which were ¥144,457,836.40, down 65.93% from ¥424,061,104.31 year-on-year[7] - Total operating costs for the current period were ¥301,267,242.96, down 52.5% from ¥634,659,929.03 in the previous period[39] - Research and development expenses increased by 90.36% to ¥19,006,039.85 compared to ¥9,984,394.66 in the same period last year[7] - Research and development expenses increased to ¥19,006,039.85, up 90.5% from ¥9,984,394.66 in the previous period[39] Liabilities and Equity - Total liabilities amounted to ¥520,264,129.08, an increase of 2.3% from ¥508,074,802.52 in the previous period[39] - Shareholders' equity attributable to the parent company was ¥7,471,775,464.59, up 2.08% from ¥7,319,750,577.78 at the end of last year[5] - Total equity attributable to shareholders reached ¥7,471,775,464.59, up 2.1% from ¥7,319,750,577.78 in the previous period[39] Non-Recurring Gains and Losses - The company has no significant changes in non-recurring gains and losses that would affect its financial reporting[19] - The company has not reclassified any non-recurring gains and losses as regular gains and losses[19]